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ABSTRACT 27 
Introduction: To determine the miRNA expression profile in placentas complicated by Preeclampsia (PE) 28 
and compare it to uncomplicated pregnancies. 29 
Methods: Sixteen placentas from women with PE, [11 with early onset PE (EOPE) and 5 with late onset PE 30 
(LOPE)], as well as 8 placentas from uncomplicated pregnancies were analyzed using miRNA microarrays. 31 
For statistical analyses the MATLAB® simulation environment was applied. The over-expression of miR-32 
518a-5p was verified using Quantitative Real-Time Polymerase Chain Reaction. 33 
Results: Forty four miRNAs were found dysregulated in PE complicated placentas. Statistical analysis 34 
revealed that miR-431, miR-518a-5p and miR-124* were over-expressed in EOPE complicated placentas as 35 
compared to controls, whereas miR-544 and miR-3942 were down-regulated in EOPE. When comparing the 36 
miRNA expression profile in cases with PE and PE- growth restricted fetuses (FGR), miR-431 and miR-37 
518a-5p were found over-expressed in pregnancies complicated by FGR.  38 
Discussion: Since specific miRNAs can differentiate EOPE and LOPE from uncomplicated placentas, they 39 
may be considered as putative PE-specific biomarkers. MiR-518a-5p emerged as a potential diagnostic 40 
indicator for EOPE cases as well as for PE-FGR complicated placentas, indicating a potential link to the 41 
severity of the disease. 42 
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ADAM A Disintegrin And Metalloproteinase 
AUC Area Under the Curve 
CDK6 Cyclin Dependent Kinase 6 
cDNA Complementary Deoxyribonucleic Acid 
EOPE Early Onset PE 
FDR False Discovery Rate 
FGR Fetal Growth Restricted Fetuses 
IGF1R Insulin Like Growth Factor 1 Receptor 
IUGR Intrauterine Growth Restriction 
LOPE Late Onset PE  
MAPK Mitogen-Activated Protein Kinases 
miRNAs MicroRNAs  
MMP Matrix Metalloproteinase 
PE Preeclampsia  
PTEN Phosphatase and Tensin homolog 
PU Proteinuria 
qRT-PCR Quantitative Real-Time Polymerase Chain Reaction 
ROC curve Receiver Operating Characteristic curve 
RUNX2 Runt-Related Transcription Factor 2 
TGF- β Transforming Growth Factor beta 
TNF Tumor Necrosis Factor 
TP53 Tumor Protein 53 
VCAM1 Vascular Cell Adhesion Molecule 1 
VEGFA Vascular Endothelial Growth Factor A 
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INTRODUCTION 51 
Preeclampsia (PE) is an obstetric complication affecting 2-8% of all pregnancies responsible for maternal, 52 
fetal and neonatal morbidity and mortality worldwide [1]. Increasing evidence suggests that both women 53 
who develop PE and their neonates have a higher risk of developing cardiovascular disease and metabolic 54 
syndromes including type II diabetes, later in life. Traditionally, PE is characterized by new onset 55 
hypertension and proteinuria after 20 weeks of gestation. Depending on the gestational age by which the 56 
symptoms develop, PE is classified as early-onset (EOPE-before 34 weeks of gestation) or late-onset (LOPE- 57 
at or after 34 weeks of gestation). Despite extensive efforts, the pathogenesis of the disease is not fully 58 
understood. EOPE shows a greater association with impaired trophoblast invasion, ischemia at the placenta 59 
and fetal growth restriction (FGR) as compared to LOPE, whereas LOPE is not often associated with 60 
placenta hypoperfusion and profound FGR [2]. 61 
MicroRNAs (miRNAs) belong to a highly conserved class of short non-coding molecules that regulate gene 62 
expression at post-transcriptional level [3]. It is estimated that 30% of human genes are transcriptionally 63 
negatively regulated by miRNAs, highlighting their crucial role in several cellular processes including cell 64 
growth, proliferation, differentiation and apoptosis [4]. Given the central role of the placenta in the 65 
development of PE, recent evidence suggests that miRNAs may be implicated in the pathogenesis of the 66 
disease regulating common pathways such as angiogenesis, hypoxia, ischemia and metabolism [5-14]. 67 
In the present study, we compared the placenta miRNA expression profiles of PE with those of 68 
uncomplicated pregnancies using a microarray hybridization based technology. The obtained miRNA 69 
patterns were correlated with clinical parameters known to be associated with PE including proteinuria, 70 
gestational age of disease onset and the presence of FGR fetus. 71 
 72 
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PATIENTS AND METHODS 74 
 75 
Patient and tissue samples 76 
Placental samples were collected from 16 women with PE (n=11 with EOPE and n=5 diagnosed with LOPE) 77 
and from 8 with uncomplicated term pregnancies at the time of cesarean section in the 3rd Department of 78 
Obstetrics and Gynecology at National and Kapodistrian University of Athens. Among the PE complicated 79 
cases, 8 carried a FGR fetus (PE-FGR): in the EOPE group, 6 out of 11 neonates had FGR confirmed by 80 
birth weight percentile below the 10th whereas in the LOPE group 1 neonate was confirmed as FGR by birth 81 
weight below the 5th percentile and the other was classified as FGR on the basis of a noted reduction of 82 
growth expressed by a static growth of abdominal velocity and abnormal placental Dopplers. Clinical 83 
characteristics of women participating in the study are summarized in Table 1. 84 
For each case, two pieces of placental tissue approximately 1×1×1cm in size were randomly obtained from 85 
the central part of the placenta maternal phase, as previously described [9]. Tissues were washed with 86 
isotonic saline solution, to remove excess of blood cells and immediately stored at-80Co until further 87 
processing. 88 
PE was defined as hypertension (blood pressure ≥140/90 mmHg) in two determinations, 4 hours apart 89 
associated with proteinuria (> 300 mg/24 h or ≥1+, according to a routine urinalysis) after 20 weeks of 90 
gestation in previously normotensive women [15]. In the absence of proteinuria, PE was characterized based 91 
on the new modified guidelines recommended by the task force on Hypertension in pregnancy [16]. In 2 out 92 
of 16 PE cases included in this study, the diagnosis was established on the presence of new onset 93 
hypertension and impaired liver enzymes concentration.  94 
FGR was diagnosed when the estimated fetal weight, calculated using the Hadlock formula (Astraia 95 
Software GmbH), was below the 10th percentile for the evaluated gestational age [17].  96 
Pregnant women with multiple pregnancies, congenital or chromosomal abnormalities of the fetus, renal 97 
disease, chronic hypertension, cardiovascular disease or other pregnancy complications were excluded from 98 
the study.  99 
The study was approved by the hospital’s ethics committee according to the Helsinki Declaration on ethical 100 
principles for medical research involving human subjects. A written consent form was obtained from all 101 
participants prior to surgery. 102 
 103 
MicroRNA extraction and expression profiling  104 
For total RNA extraction, 100mg of placental tissue were mechanically homogenized in TRIzol (Life 105 
Technologies, Foster City, CA), treated with DNase I (Ambion, Austin, USA) and enriched for small RNAs 106 
(siRNAs, miRNAs) using the mirVana microRNA Isolation kit (Ambion, Austin, USA). RNA quantity and 107 
purity were measured using a Nanodrop spectrophotometer (ND-1000, NanoDrop Technologies, Houston, 108 
TX, USA). 109 
Labeling and hybridization were performed using the LabelIT miRNA labeling kit (Mirus Bio LLC, USA) 110 
according to the manufacturer’s instructions. Samples were hybridized to an Applied MicroArrays (miRlink 111 
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Bioarray 300054-3PK) platform containing 1211 human miRNAs (Applied Biosystems, Foster City, CA). 112 
This platform consists of 8 arrays per slide and on each array miRNAs are represented by multiple replicates. 113 
Images were scanned using an Agilent Microarray Scanner (G2565CA). 114 
 115 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 116 
The differential expression of miR-518a-5p in PE complicated placentas, as compared to the control group, 117 
was verified using Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Complementary DNA 118 
(cDNA) synthesis and subsequent RT-PCR were performed, using the TaqMan miRNA Reverse 119 
Transcription kit and TaqMan universal PCR master mix (Applied Biosystems, Inc., USA) respectively. 120 
Specific primers and a TaqMan probe for miR-518a-5p (PN4427975, Applied Biosystems, Inc., USA) were 121 
used according to the manufacturer’s instructions. All samples were analyzed in triplicate in an LC480 122 
LightCycler system (Roche GmbH, Switzerland). Positive amplification of each sample was considered 123 
when a signal occurred before 40th threshold cycle. The miRNA levels were normalized to RNU44 (Applied 124 
Biosystems, Inc., USA) as an internal control and the relative abundance of each miRNA was calculated 125 
using the ΔΔCt equation.  126 
 127 
Data analyses and statistics 128 
Microarray Data Extraction and Analysis 129 
Microarray raw data were extracted, as previously described, using the Imagene 6.0 software (Biodiscovery 130 
Inc., USA) [18]. The MATLAB® simulation environment (The Mathworks, Inc, Natick, MA) was applied 131 
for multi-parameter analyses. Background correction was performed by subtracting the median local 132 
background from the signal intensity. Normalization was performed using the quantile normalization 133 
algorithm. The two-tailed student t-test was used to assess the mean differences between the two groups. 134 
Relative expression was estimated as the log2-transformed ratio of the individual miRNA expression levels 135 
over the mean expression level of all control samples for the respective miRNA under investigation. Final 136 
miRNA values have been calculated as the mean of each specific miRNA replicates on each array. 137 
Continuous variables were expressed as median ± standard deviation, unless differently indicated. MiRNAs 138 
were considered significant if they had a p-value<0.05 and False Discovery Rate (FDR)≤0.05. Microarray 139 
platform as well as raw data have been uploaded on the Gene Expression Omnibus (GEO) database 140 
(https://www.ncbi.nlm.nih.gov/geo/) with reference numbers GPL23980 and GSE103542 respectively. 141 
 142 
Group-wise Comparison of miRNA expression and clinical data 143 
MiRNA expression values were compared with clinical parameters, including PE (EOPE and LOPE), as well 144 
as the presence of proteinuria and FGR with the Kruskal-Wallis test. Bonferroni correction was used in order 145 
to adjust p-values for the statistical test performed and reduce the chances of obtaining false-positive results 146 
(type I errors) with the multiple pair-wise tests performed on the present dataset. Differences were 147 




ROC Analysis 151 
Receiver Operating Characteristic (ROC) curves were performed with the MATLAB® simulation 152 
environment (The Mathworks, Inc, Natick, MA) to evaluate the diagnostic potential of differentially 153 
expressed miRNAs with 95% Standard Error (SE) and 95% Confidence Intervals (CI). ROC curves were 154 
considered significant when an Area Under the Curve (AUC) value > 0.8 at a p < 0.05 was obtained. 155 
 156 
MiRNA Enrichment, Gene Ontology and Pathway Analysis 157 
Differentially expressed miRNAs were further enriched and analyzed for known functions and pathway 158 
participation. Functional annotation was performed using Webgestalt web-tool [19]. RNA target prediction 159 
for selected miRNAs was performed with TargetScan v.7.0 [20], DIANA tools [21-23] and the miROB 160 
annotation web tool (http://mirob.interactome.ru/). Further on, we have used the GOmiR [24] multi-compare 161 
tool for a more in-depth functional annotation of investigated microRNAs. 162 
 163 




MicroRNA expression profiles between PE and the control group 167 
Overall, 44 miRNAs were dysregulated in PE-complicated placentas, as compared to the control cohort,  168 
with a two-fold change and statistical significance (p < 0.05) (Figure 1). The vast majority was up-regulated 169 
with a total of 27 miRNAs (61.4%) showing over-expression and 17 (38.6%) decreased expression. 170 
 171 
MicroRNA expression in early-onset and late-onset PE  172 
When comparing miRNA expression in samples obtained from women with EOPE (n=11) and LOPE (n=5) 173 
with controls (n=8), 9 miRNAs were found associated with the early or the late type of the disease (Figure 174 
2). Specifically, miR-431 (p=0.003), miR-518a-5p (p=0.002) and miR-124* (p=0.001) were significantly 175 
over-expressed in EOPE complicated placentas, as compared to controls, whereas miR-544b (p=0.001) was 176 
significantly down-regulated and miR-3942 was marginally down-regulated (p=0.02) in EOPE when 177 
compared to controls. Further on, miR-130b (p=0.004) and miR-423-3p (p=0.001) were significantly up-178 
regulated in EOPE placentas as compared to controls, while miR-383 was marginally up-regulated in EOPE  179 
(p=0.02) and significantly up-regulated (p=0.01) in LOPE samples. MiR-1183 was marginally up-regulated 180 
(p=0.02) in LOPE samples, as compared to controls. In the EOPE placentas, following Bonferroni 181 
correction, the over-expression of miR-1183 was not considered significant (p=0.03). 182 
 183 
MicroRNA expression in pregnancies complicated by FGR 184 
The miRNA expression profile was also compared in cases of PE and PE-FGR. Two miRNAs were found 185 
overexpressed in PE-FGR complicated placentas, including miR-431 and miR-518a-5p (Figure 3). 186 
 187 
ROC analysis 188 
ROC analysis revealed that 8 miRNAs up-regulated in PE complicated placentas (miR-500a, miR-383, miR-189 
518a-5p, miR-431, miR-423-3p, miR-124*, miR-1183 and miR-130b) and 2 down-regulated (miR-3942, 190 
miR-544b) were associated with PE and miRNAs with p<0.05 and AUC>0.8 were considered as potential 191 
biomarkers. The ROC curves yielded the following AUCs: miR-500a (AUC=0.8), miR-3942 (AUC=0.8), 192 
miR-544b (AUC=0.84), miR-383 (AUC≈0.82), miR-518a-5p (AUC=0.83), miR-431 (AUC=0.82), miR-423-193 
3p (AUC≈0.90), miR-124* (AUC=0.88), miR-1183 (AUC=0.80) and miR-130b (AUC=0.82) (Figure 4). 194 
 195 
qRT PCR verification  196 
The over-expression of miR-518a-5p in PE complicated placentas as compared to controls was verified using 197 
qRT-PCR in all samples. Consistent with microarray results the change of dysregulated miRNA was 198 





MiRNA Enrichment, Gene Ontology and Pathway Analysis 203 
Several genes have been reported as predicted or verified targets of the aforementioned miRNAs. 204 
Specifically, miR-126*, miR-885, miR-130B, miR-1915, miR-1204, miR-3928, miR-518a-5p, miR-631, 205 
miR-383, miR-19a, miR-302c, miR-155, miR-30a, miR-542 and miR-1248 manifested significant 206 
associations with genes including SMAD1/2/4/5, ADAM9, VCAM1, TGFBP2, PTEN, TP53 and RUNX2 207 
(Figure 2 suppl.). Pathway analysis of significantly annotated miRNAs and their respective targets revealed 208 
that they participate in biological pathways associated with PE including MAPK, TNF signaling, T-cell 209 
receptor, B-cell receptor and TGF-β pathways (Figure 5). Further on, the GOmiR tool searches in the 210 
MiRanda, TargetScan, PicTar, Sanger, RNAhybrid databases unraveled common gene and functional targets 211 
for all the aforementioned miRNAs. In particular, GOmiR confirmed the results obtained by the other tools, 212 
revealing that miR-126* and miR-130B target genes participate in TNF-signaling. It also revealed PPARG, 213 
another target gene, which participates in obstetric diseases such as Polycystic Ovary Syndrome, Ovarian 214 
Cysts, Ovarian Diseases and Metabolic Syndrome. In addition, GOmiR confirmed that miR-518a-5p 215 
participates in MAPK signaling. Further on, miR-631 was found to target TBX2, HDAC1 and AXIN1 which 216 
participate in ectodermal placode formation. Target genes of the miR-631 were shown to participate in 217 
metabolic pathways and the insulin signaling pathway, whereas miR-30a target genes are involved in 218 
MAPK, JAK-STAT signaling pathways as well as in metabolic pathways. 219 
 220 
  221 
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DISCUSSION 222 
Several studies have demonstrated dysregulation of placenta miRNAs in PE, implying their involvement in 223 
the pathogenesis of the disease by targeting a variety of genes and regulating crucial biological pathways [5-224 
7, 10, 11, 14, 25, 26]. Despite extensive efforts, however, conflicting results exist which may be attributed to 225 
the small number of samples included in each study, the increased number of molecules analyzed, the 226 
position of the placenta from which samples are obtained, the gestational age at sampling and the differences 227 
in the platforms used for analysis [7]. 228 
In the present study, 44 miRNAs were found dysregulated in PE complicated placentas. The results obtained 229 
verified the differential expression of several miRNAs previously reported, including the over-expression of 230 
miR-155 and miR-130b, as well as the down-regulation of miR-126* [11,25, 27-35].  231 
MiR-155 and miR-130b have been implicated in the pathogenesis of PE through their involvement in 232 
pathways regulating trophoblast cells such as TGF-β signaling [11, 27-30]. Recently, miR130b was reported 233 
as differentially expressed in relation to pre-pregnancy BMI and adipogenesis, both of which have been 234 
associated with increased risk for the development of pregnancy complications including PE [31-33]. 235 
Although conflicting results exist regarding the role of mir-126 in the pathogenesis of PE, miR-126 and its 236 
isoform 126* regulate many target genes mainly related to angiogenesis [25, 34, 35]. Notably, in vitro 237 
experiments, using endothelial cells, revealed that miR-126 positively regulates their migration and 238 
proliferation, by enhancing fibroblast growth during arterial development [35]. Lack of miR126 has a 239 
negative angiogenic response, through VEGFA, bFGF and MAP kinase [34, 36]. In the current study, in 240 
silico analysis also revealed that miR126* can potentially modulate ADAM9, MMP7, MMP13, VEGFA and 241 
VCAM1. Proteins encoded by these genes are currently under investigation as potential biomarkers for the 242 
identification of pregnant women destined to develop PE.  243 
Over-expression of miR-423-3p, miR-124*, miR-500a, miR-431 and miR-1305 and down-regulation of 244 
miR-544 and miR-3942 were observed in PE complicated placentas, as compared to controls. These 245 
miRNAs have not been previously associated with the pathogenesis of PE. MiR-423-3p, has been linked to 246 
renal function, acute kidney injury and cell proliferation [37, 38]. MiR-124 has been implicated in 247 
angiogenesis through the renin-angiotensin system and is hence linked with the regulation of blood pressure 248 
[39]. MiR-1305 has been recently implicated in cell cycle regulation and apoptosis in pluripotent stem cells 249 
by targeting CDK6, CYCLIND2 and RUNX2 [40]. Mir-431, a member of C14MC placenta cluster, directly 250 
regulates the expression of SMAD4 [41]. Over-expression may negatively regulate IGF1R and consequently 251 
inhibit cell proliferation through MAPK pathway, which plays an important role in the development of 252 
vascular lesions that are observed in diabetes and hypertension [42]. 253 
Results were also analyzed with respect to the gestational age of disease onset. In the literature, a limited 254 
number of studies have focused on comparisons between miRNA expression pattern in EOPE and LOPE. In 255 
the current study, when correlations between EOPE, LOPE and the control cohort were performed, 9 256 
miRNAs were found aberrantly expressed. Specifically, miR-383 and miR-1183 were over-expressed in PE, 257 
higher in LOPE cases as compared to controls, possibly reflecting an association with a milder form of the 258 
disease.  Additionally, higher levels of expression for miR-518a-5p, miR-423, miR-124* and miR-431 were 259 
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detected in EOPE as compared to controls. It seems likely that all four miRNAs are associated with the 260 
severity of the disease and the severity of the clinical symptoms. On the contrary, miR-544 and miR-3942 261 
were down-regulated in the EOPE cases, indicating a putative PE-specific diagnostic marker. Mir-130b was 262 
found over-expressed in the EOPE cases when compared to the LOPE, signifying its potential use as a 263 
biomarker for severe PE.  264 
When examining miRNA expression profiles in PE complicated by FGR, miR-518-5p and miR-431 were up-265 
regulated in all PE-FGR cases, indicating their potential as unfavorable prognostic markers. It is noticeable 266 
that overexpression of both miRNAs was also observed in previous correlations, reinforcing the prediction 267 
about their possible linkage to poor PE outcomes when up-regulated. 268 
Although the properties of miR-518a-5p remain to be elucidated, statistically significant over-expression was 269 
found in all associations performed in the present study, including PE diagnosis, EOPE, LOPE and PE-FGR 270 
following ROC analysis. Vashukova et al., reported up-regulation of miR-518a-5p in superimposed PE on 271 
chronic hypertension [43]. The aforementioned observation, along with the data obtained in the present 272 
study, possibly indicate a common pathway in the pathogenesis of EOPE, superimposed PE and PE-FGR. 273 
Since miR-518a-5p is also expressed in maternal peripheral blood during pregnancy, it represents a potential 274 
noninvasive diagnostic biomarker for all types of PE [10]. These findings however, should be validated in 275 
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FIGURE LEGENDS 403 
Figure 1. Histogram of the 44 dysregulated miRNAs in PE complicated placentas as compared to controls (p<0.05 and FDR≤0.05). Over-expressed miRNAs are 404 
indicated with upward bars and down-regulated with downward bars. Y axis values represent miRNA fold change (ratios presented include Early Onset 405 
Preeclampsia (EOPE) (n=11) and Late Onset Preeclampsia (LOPE) (n=5). 406 
 407 
Figure 2. Differences in miRNA expression in EOPE, LOPE and control placentas. Significant differential expression was identified for (A) miR-3942 between 408 
EOPE and controls (p=0.02), (B) miR-544b between EOPE and controls (p=0.001), (C) miR-383 between EOPE and controls as well as LOPE and controls (p=0.02 409 
and p=0.01 respectively), (D) miR-518a-5p between EOPE and controls (p=0.002), (E) miR-431 between EOPE and controls (p=0.003), (F) miR-423-3p between 410 
EOPE and controls as well as LOPE and controls (p=0.001 and p=0.007 respectively), (G) miR-124* between EOPE and controls (p=0.001), (H) miR-1183 between 411 
EOPE and controls as well as LOPE and controls (p=0.03 and p=0.02 respectively) and (I) miR-130b between EOPE and controls as well as LOPE and controls 412 
(p=0.004 and 0.04 respectively) (EOPE: Early Onset Preeclampsia, LOPE: Late Onset Preeclampsia) (Expression levels concern the natural, log2 untransformed 413 
miRNA expression values. * depicts a significance at the p<0.05 level and ** depicts a significance at the p<0.01 level). 414 
 415 
Figure 3. Over-expression of (A) miR-518a-5p and (B) miR-431 in PE complicated placentas with FGR fetuses as compared to those with unaffected fetal growth 416 
(PE: Preeclampsia, FGR: Fetal Growth Restriction) (Expression levels correspond to the natural log2 untransformed expression values. Differences were significant 417 
at p<0.05). 418 
 419 
Figure 4. Receiver Operating Characteristic (ROC) curves of miRNAs differentiating controls from Preeclampsia complicated placentas. Ten miRNAs can 420 
differentiate controls from Preeclampsia complicated placentas: (A) miR-500a, (B) miR-03942, (C) miR-544b, (D) miR-383, (E) miR-518a-5p, (F) miR-431, (G) 421 
miR-423-3p, (H) miR-124*, (I) miR-1183 and (J) miR-130b manifested an Area Under the Curve (AUC) value greater than 0.8 (AUC>0.8) and p<0.05, suggesting 422 
that they are possible candidates for Preeclampsia. 423 
Figure 5. Selected significant signaling pathways associated with annotated differentially expressed miRNAs (miR-125b, miR-155-5p, miR-21-5p and miR-145). 424 
MiRNA annotation was performed with the DIANA mIRNA web annotation tool http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath/index). 425 
 17 







p-value1 p-value2 p-value3 p-value4 
Maternal Age (y) 35.7 [35-39] 35.1 [28-45] 28.4 [20-35] 0.051 0.820 0.036 0.055 
Pre-pregnancy BMI (kg/m2) 29.2 [22.96-31.99] 29.9 [19.83-41.77] 28.6[24.02 –36.57] 0.942 0.835 0.867 0.778 
Blood Pressure (mmHg)        
Systolic 121 [122-118] 197.75 [160-250] 172.25 [152-197] 0.702 0.889 0.612 0.412 
Diastolic 75 [72-85] 113.5 [90-150] 107.75 [94-135] 0.966 0.962 0.923 0.798 
Proteinuria (n)        
Yes 0 10 (91%) 4 (80%) 
0.0002¥ 
   
No 8 (100%) 1 (9%) 1 (20%)    
Fetal Growth Restriction (FGR) None 6 (54.5%) 2 (40%)     
Gestational Age at delivery (wk) 36.3 [34.2 – 38.5] 31.2 [28 – 33.5] 35.6 [34.4 – 37.3] 0.051 0.0003 0.29 0.78 
Fetal Birth Weight (grams) 2792.6 [2215 - 3560] 1335 [1025 - 1540] 2454 [1900 - 3020] 0.0003 0.0002 0.336 0.002 
>10th percentile (n) 8 (100%) 5 (45.4%) 3 (60%)     
<10th percentile (n) 0 4 (36.4%) 1 (20%)     
<5th percentile (n) 0 2 (18.2%) 1 (20%)     
*EOPE: Early onset Preeclampsia ** LOPE: Late onset Preeclampsia 
1Significance level between all groups 
2Significance level between Control and EOPE placentas 
3Significance level between Control and LOPE placentas 
4Significance level between EOPE and LOPE placentas 






































SUPPLEMENTARY FIGURES 461 
 462 
Supplementary Figure 1. 463 




Supplementary Figure 2. Networks of miRNAs and their 467 
association with target genes. In particular, we have found 468 
that miR-126, miR-885, miR-130b, miR-1915, miR-1204, 469 
miR-3928, miR-518a1, miR-126, miR-631, miR-383, 470 
miR-19a, miR-302c, miR-155, miR-30a, miR-542, miR-471 
1248, manifested significant associations with gene 472 
groups. miRNA annotation was performed with the 473 
miROB web tool (http://mirob.interactome.ru/). 474 
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